multiMED markets and sells quality rapid diagnostics that help healthcare providers, public health agencies, and individuals prevent and control the spread of infectious diseases like HIV and Hepatitis.
The global market for in-vitro diagnostics (IVD) has been estimated by independent research groups to be in the region of $38 billion with the expectation of annual growth to be around 9%. With the diagnosis of patients representing on average 6% of total costs within a nation’s healthcare system, while directly influencing over 60% of total costs, the use of rapid tests provides an accurate and cost effective alternative to screening to obtain early diagnosis to facilitate both treatment and prevention of many diseases.
Rapid tests symbolize a key part to sustainable health solutions for the developing as well as the developed world’s fight against the spread of diseases whilst significantly reducing health care expenditures.
Most advanced rapid diagnostics
FDA CE and China approved
Instant results
Easy for mass testing
Single & multiple disease tests
Patented Technology
Decreased costs
A safer world!